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Background: Transforming growth factor, beta (TGFB) signal is considered to be a tumor suppressive pathway
based on the frequent genomic deletion of the SMAD4 gene in pancreatic cancer (PC); however; the role of the
activin signal, which also belongs to the TGFB superfamily, remains largely unclear.
Methods and results: We found a homozygous deletion of the activin A receptor, type IB (ACVR1B) gene in 2 out
of 8 PC cell lines using array-comparative genomic hybridization, and the absence of ACVR1B mRNA and protein
expression was confirmed in these 2 cell lines. Activin A stimulation inhibited cellular growth and increased the
phosphorylation level of SMAD2 and the expression level of p21CIP1/WAF1 in the Sui66 cell line (wild-type ACVR1B
and SMAD4 genes) but not in the Sui68 cell line (homozygous deletion of ACVR1B gene). Stable ACVR1B-knockdown
using short hairpin RNA cancelled the effects of activin A on the cellular growth of the PC cell lines. In addition,
ACVR1B-knockdown significantly enhanced the cellular growth and colony formation abilities, compared with controls.
In a xenograft study, ACVR1B-knockdown resulted in a significantly elevated level of tumorigenesis and a larger tumor
volume, compared with the control. Furthermore, in clinical samples, 6 of the 29 PC samples (20.7%) carried a deletion
of the ACVR1B gene, while 10 of the 29 samples (34.5%) carried a deletion of the SMAD4 gene. Of note, 5 of the
6 samples with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene.
Conclusion: We identified a homozygous deletion of the ACVR1B gene in PC cell lines and clinical samples and
proposed that the deletion of the ACVR1B gene may mediate an aggressive cancer phenotype in PC. Our findings
provide novel insight into the role of the activin signal in PC.
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Pancreatic cancer (PC) is a devastating disease. Gemcitabine
has been the standard therapy for experimental regimens
in patients with advanced PC for over a decade, but re-
cently, the overall survival has been significantly prolonged
using combination therapies, such as gemcitabine plus er-
lotinib or a combination of oxaliplatin, irinotecan, fluoro-
uracil and leucovorin (FOLFIRINOX) [1-3]. Despite some
recent progress, however, the overall survival rate of pa-
tients with PC is still less than 5% [4]. The model explaining* Correspondence: knishio@med.kindai.ac.jp
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unless otherwise stated.the progression of PC is influenced by multiple genetic al-
terations. During early genetic events, such as activating
point mutations in the K-ras oncogene and the overex-
pression of the HER-2/neu gene, pancreatic duct lesions
show minimal cytological and architectural atypia. The in-
activation of the p16 tumor suppressor gene appears to
occur at a later stage, followed by the loss of the p53,
SMAD4, and BRCA2 tumor suppressor genes [5-8]. For
instance, the HER-2/neu gene is not expressed in the epi-
thelium lining of normal pancreatic duct, but it is highly
expressed in pancreatic intraepithelial neoplasia [9]. How-
ever, two clinical trials assessing anit-HER2 trastuzumabl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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duced disappointing results [10,11]. Although such recent
breakthroughs in the molecular biology of PC have assisted
in translational research, creating hope for individualized
therapy and better disease management, the inhibition of
epidermal growth factor receptor using erlotinib is, to
date, the only targeted approach that has been demon-
strated to result in a survival [1]. Therefore, further under-
standing of the molecular biology of PC is needed.
The transforming growth factor, beta (TGFB) receptor
II (TGFBR2) and SMAD4 genes are commonly inactivated
in several types of cancer, providing evidence that the
TGFB signal functions as a tumor suppressor [12,13].
Thirty percent of colorectal cancers are thought to con-
tain a mutation in the TGFBR2 gene. The human locus
18q21, which encodes the SMAD2 and SMAD4 genes, is
often mutated or lost completely in several cancers. The
loss of the SMAD4 gene eliminates the classic SMAD2/
3/4 heteromeric complexes that have been implicated in
a large number of TGFB-dependent transcriptional regu-
latory complexes. As a result, TGFB-mediated growth
inhibition is lost. The SMAD4 gene is inactivated in 55%
of PC tumors, and numerous studies on TGFB signal in
PC have been reported. The loss of the SMAD4 gene is
correlated with both a poor prognosis and the develop-
ment of widespread metastases in patients. The TGFBR2
gene is also altered in a smaller subset of PC tumors
[5-7,14,15]. In addition, pancreatic-specific TGFBR2 or
SMAD4-knockout mice with active K-ras expression de-
veloped PC [16,17]. However, the roles of defects other
than those in the SMAD4 and TGFBR2 genes in PC re-
main unclear, and few studies regarding the activin signal,
which also belongs to the TGFB superfamily, have been
reported [18-20]. Defects in several genes involved in the
activin signal pathway have been characterized in several
cancers. For instance, two 8-bp polyadenine tracts in the
activin A receptor, type IIA (ACVR2A) gene were reported
to be targets for frameshift mutations in gastrointestinal
cancers with microsatellite instability [21]. Similarly, the
activin signal induces growth inhibition and apoptosis
mainly through SMAD-dependent pathways in many
other cancers [22-27]. Thus, the dysregulation of the
activin signal is directly involved in carcinogenesis. In
contrast, however, a recent study has demonstrated that
Nodal/Activin signal is associated with self-renewal and
the tumorigenicity of PC stem cells [20]; thus, the role
of activin signal in pancreatic carcinogenesis remains
controversial. In the present study, we identified a
homozygous deletion of the activin A receptor, type IB
(ACVR1B) gene in PC cell lines using array-comparative
genomic hybridization (array-CGH). Furthermore, we
investigated the role of this homozygous deletion in PC
cell lines and the status of the ACVR1B gene in clinical
samples of PC.Results
Identification of homozygous deletion of ACVR1B gene in
PC cell lines
The results of an array-CGH demonstrated the homozy-
gous deletion of the ACVR1B gene in the Sui65 and
Sui68 cell lines (chromosome 12) and the homozygous
deletion of the SMAD4 gene in the Sui65, Sui70, and
Sui71 cell lines (chromosome 18) (Figure 1A and B). No
deletions of other SMAD genes or other main TGFB
and activin receptors, including the TGFBR1, TGFBR2,
ACVR2A, ACVR2B, SMAD2 genes, were found. To exam-
ine the ACVR1B and SMAD4 gene copy numbers in the
PC cell lines, we used a real-time PCR-based detection
method, the TaqMan Copy Number Assay, and the ex-
periment was performed in triplicate. The copy number
results are summarized in Table 1. The copy number of
the ACVR1B gene in the Sui68 cell line was 0 and that in
the Sui65 cell line was nearly 0 (0.115 ± 0.025). The copy
numbers of the SMAD4 gene in the Sui65, Sui70, and
Sui71 cell lines were all 0. These results were similar to
those of the array-CGH.
mRNA and protein expressions of ACVR1B and SMAD4 in
PC cell lines
To examine the mRNA expressions of the ACVR1B and
SMAD4 genes, we performed real-time reverse tran-
scription PCR (RT-PCR) using samples of normal pan-
creatic tissue from Clontech and PC cell lines. ACVR1B
mRNA was scarcely expressed in the Sui65 and Sui68 cell
lines, and SMAD4 mRNA was also scarcely expressed in
the Sui65, Sui70, and Sui71 cell lines (Figure 2A). These
results were similar to those for the array-CGH and copy
number assay (Table 1). Western blot analyses were per-
formed and showed that ACVR1B was scarcely expressed
in the Sui65 and Sui68 cell lines and that SMAD4 was
scarcely expressed in the Sui65, Sui70, and Sui71 cell
lines. The protein expressions of ACVR1B and SMAD4
reflected the mRNA expression levels (Figure 2B).
Influence of activin A on cellular growth and cell cycle in
PC cell lines
To examine the influence of ligands in the PC cell lines,
we performed cellular growth assays using the Sui65
(homozygous deletion of ACVR1B and SMAD4 genes),
Sui66, Sui73 (wild-type ACVR1B and SMAD4 genes),
Sui68 (homozygous deletion of ACVR1B gene and wild-
type SMAD4 gene), and Sui70 (wild-type ACVR1B and
homozygous deletion of SMAD4 gene) cell lines in the
presence of ligands. Based on numerous previous stud-
ies and our data on cellular growth inhibition [22,28],
we used concentrations of 0.1, 1, or 10 ng/mL of TGFB1
or 1, 10, or 100 ng/mL of activin A. TGFB1 inhibited
cellular growth in the Sui66, Sui68, and Sui73 cell lines
(Figure 3B, C, and D). Activin A did not influence cellular




Source Histology ACVR1B SMAD4
CN Expression CN Expression
Sui65 Peritoneum Tubular 0 - 0 -
Sui66 Pancreas Tubular 1 + 2 ++
Sui67 Pancreas Tubular 1 - 1 +
Sui68 Pancreas Ad 0 - 1 +
Sui70 Pancreas Ad 2 + 0 -
Sui71 Liver Ad 1 + 0 -
Sui73 Pancreas Tubular 2 + 2 +
Sui74 Pancreas Tubular 1 + 1 -
ACVR1B, activin receptor A, type IB; Tubular, tubular adenocarcinoma; Ad,
adenocarcinoma; CN, gene copy number.
Legend: The copy numbers of the ACVR1B gene in the Sui65 and Sui68 cell
line was 0, and the copy numbers of the SMAD4 gene in the Sui65, Sui70, and
Sui71 cell lines were all 0. ACVR1B mRNA was scarcely expressed in the Sui65
and Sui68 cell lines, and SMAD4 mRNA was also scarcely expressed in the
Sui65, Sui70, and Sui71 cell lines. These results were similar to those for the
copy number assay.
Figure 1 Array-CGH of PC cell lines. A gain (>4 copies, red) and a deletion (<0.5 copies, blue) of genomic copy number are shown. (A) Array-CGH
of chromosome 12. The homozygous deletion of the ACVR1B gene was found in the Sui65 and Sui68 cell lines. (B) Array-CGH of chromosome 18. The
homozygous deletion of the SMAD4 gene was found in the Sui65, Sui70, and Sui71 cell lines.
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C), although it inhibited cellular growth in the Sui66 and
Sui73 cell lines (Figure 3B and D). In addition, the Sui70
cell line was not influenced by either TGFB1 or activin A
(Additional file 1A).
Next, cell cycle distribution analyses were also per-
formed. Both TGFB1 and activin A increased the pro-
portion of cells in the G0/G1 phase and decreased the
proportion of cells in the S phase in the Sui66 and
Sui73 cell line (Figure 4B and D). In the Sui68 cell line,
however, TGFB1 increased the proportion of cells in the
G0/G1 phase and decreased the proportion of cells in
the S phase, while activin A did not affect the cell cycle
distribution (Figure 4C). In the Sui65 cell line, activin
A did not affect the cell cycle distribution, either
(Figure 4A). These results indicate that activin A in-
hibits cellular growth and induces G1 phase cell arrest
in PC cell lines with wild-type ACVR1B, while activin A
does not inhibit cellular growth and does not influence
the cell cycle in cell lines with a homozygous deletion of
the ACVR1B gene.
Figure 2 Expression of ACVR1B and SMAD4 in PC cell lines. (A) mRNA expression levels of the ACVR1B and SMAD4 genes in normal
pancreatic tissue (RNA from Clontech) and PC cell lines. The expressions were analyzed using real-time RT-PCR. ACVR1B mRNA was scarcely
expressed in the Sui65 and Sui68 cell lines, and SMAD4 mRNA was also scarcely expressed in the Sui65, Sui70, and Sui71 cell lines. Rel mRNA,
normalized mRNA expression levels (ACVR1B or SMAD4/GAPD × 106); Columns, mean of independent triplicate experiments; Bars, SD. (B) Western
blot analysis of ACVR1B and SMAD4 in PC cell lines. ACVR1B was scarcely expressed in the Sui65 and Sui68 cell lines. SMAD4 was scarcely
expressed in the Sui65, Sui70, and Sui71 cell lines. The findings confirmed the array-comparative genomic hybridization results. β-actin was used
as an internal control.
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induction in PC cell lines
Activin A inhibited the cellular growth of cell lines with
wild-type ACVR1B and SMAD4 genes; therefore, we ex-
amined the downstream signal under TGFB1 or activin
A stimulation. Based on numerous previous studies and
our data on cellular growth inhibition [22,28], we used
1 ng/mL of TGFB1 or 10 ng/mL of activin A. The time
points were also decided based on the previous studies
[22,28]. In the Sui66 cell line (wild-type ACVR1B and
SMAD4 genes), both TGFB1 and activin A increased the
phosphorylation levels of SMAD2 (Figure 5A); these ef-
fects were cancelled by the ACVR1B/TGFBR1/ACVR1C-
specific inhibitor SB431542 (Figure 5C). In the Sui68 cell
line (homozygous deletion of ACVR1B gene and wild-type
SMAD4 gene), TGFB1, but not activin A, increased the
phosphorylation levels of SMAD2 (Figure 5A); these ef-
fects were cancelled by SB431542 (Figure 5C). These re-
sults suggest that activin A activates the SMAD signal in amanner similar to TGFB1 in PC cell lines with the wild-
type ACVR1B gene, but does not activate in PC cell lines
with the homozygous deletion of the ACVR1B gene.
Next, we evaluated the expression levels of p21CIP1/WAF1.
p21CIP1/WAF1 is a major cdk inhibitor and is a hallmark of
the cytostatic role of the TGFB signal pathway [29]. TGFB
and activin A are known to increase p21 expression
[22,28]. The expression of p21 was evaluated in whole-cell
lysates. p21 expression was increased by both TGFB1
and activin A in the Sui66 cell line. In the Sui68 cell line,
however, its expression was increased only by TGFB1
(Figure 5B). Therefore, we speculated that p21 may have
a role in activin A-mediated growth inhibition and cell-
cycle progression.
To evaluate the effect of activin A on SMAD4-independent
pathways, the phosphorylation of ERK1/2 and AKT, which
are representative signals of SMAD4-independent path-
ways, was investigated in the Sui70 cell line (wild-type
ACVR1B and homozygous deletion of SMAD4 genes).
Figure 3 Influence of TGFB1 and activin A on cellular growth. The cells were stimulated with the indicated doses of TGFB1 or activin A for
72 hours. Cell proliferation was assayed using an MTT assay. (A) Cellular growth of Sui65 cell line (homozygous deletion of ACVR1B and SMAD4
genes). Both TGFB1 (0.1 ng/mL, P = 0.56; 1 ng/mL, P = 0.51; 10 ng/mL, P = 0.69) and activin A (1 ng/mL, P = 0.51; 10 ng/mL, P = 0.71; 100 ng/mL,
P = 0.65) did not influence the cellular growth. (B) Cellular growth of Sui66 cell line (wild-type ACVR1B and SMAD4 genes). Both TGFB1 (0.1 ng/mL,
P = 0.0049*; 1 ng/mL, P = 0.0028*; 10 ng/mL, P = 0.0016*) and activin A (1 ng/mL, P = 0.051; 10 ng/mL, P = 0.010*; 100 ng/mL, P = 0.0081*)
inhibited cellular growth. (C) Cellular growth of Sui68 cell line (homozygous deletion of the ACVR1B gene and wild-type SMAD4 gene). TGFB1
inhibited cellular growth (0.1 ng/mL, P = 0.011*; 1 ng/mL, P = 0.013*; 10 ng/mL, P = 0.0039*), but activin A did not influence the cellular growth
(1 ng/mL, P = 0.65; 10 ng/mL, P = 0.93; 100 ng/mL, P = 0.82). (D) Cellular growth of Sui73 cell line (wild-type ACVR1B and SMAD4 genes). As is seen
in the Sui66 cell line, both TGFB1 (0.1 ng/mL, P = 0.072; 1 ng/mL, P = 0.0087*; 10 ng/mL, P = 0.0066*) and activin A (1 ng/mL, P = 0.21; 10 ng/mL,
P = 0.0018*; 100 ng/mL, P = 0.028*) inhibited cellular growth. hDEL, homozygous deletion; WT, wild-type; Columns, mean of independent triplicate
experiments; Bars, SD; *P < 0.05.
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(Additional file 1B). Particularly, both AKT and ERK1/2
were phosphorylated before the stimulations. The expres-
sion of p21 also remained unchanged.
Enhanced cellular growth and colony formation, but no
response to activin A, of Sui66/shACVR1B and
Sui73/shACVR1B cell lines
To evaluate the role of the ACVR1B gene, we examined
the colony formation and the cellular growth of stable
ACVR1B-knockdown cell lines (Sui66/shACVR1B-1,
Sui66/shACVR1B-2, Sui73/shACVR1B-1, and Sui73/
shACVR1B-2) or control cell lines (Sui66/shScr-1, Sui66/shScr-2, Sui73/shScr-1, and Sui73/shScr-2) (Figure 6A).
Activin A did not increase the phosphorylation level of
SMAD2 in the Sui66/shACVR1B-1, Sui66/shACVR1B-2,
Sui73/shACVR1B-1, or Sui73/shACVR1B-2 cell lines
(Figure 6A). Although activin A inhibited the cellular
growth of the Sui66/shScr-1, Sui66/shScr-2, Sui73/shScr-1,
and Sui73/shScr-2 cell lines, it did not influence the cellular
growth of the Sui66/shACVR1B-1, Sui66/shACVR1B-2,
Sui73/shACVR1B-1, or Sui73/shACVR1B-2 cell lines
(Figure 6B). The colony formation and cellular growth
of the Sui66/shACVR1B-1, Sui66/shACVR1B-2, Sui73/
shACVR1B-1, and Sui73/shACVR1B-2 cell lines were also
enhanced, compared with the controls (Figure 6C and D).
Figure 4 Influence of TGFB1 and activin A on the cell cycle. The cell lines were exposed to the ligands (TGFB1, 1 ng/mL; activin A, 10 ng/mL)
for 48 hours. The cells were then stained using propidium iodide/RNase Staining Buffer and were analyzed using a flow cytometer. (A) Cell cycle
distribution of Sui65 cell line (homozygous deletion of ACVR1B and SMAD4 genes). Both TGFB1 and activin A did not influence the cell cycle
distribution. (B) Cell cycle distribution of Sui66 cell line (wild-type ACVR1B and SMAD4 genes). Both TGFB1 and activin A increased the proportion
of cells in G0/G1 phase (P = 0.0039* and 0.031*, respectively) and decreased the proportion of cells in S phase (P = 0.0043* and 0.039*,
respectively). (C) Cell cycle distribution of Sui68 cell line (homozygous deletion of the ACVR1B gene and wild-type SMAD4 gene). TGFB1 increased
the proportion of cells in G0/G1 phase (P = 0.0016*) and decreased the proportion of cells in S phase (P = 0.019*), while activin A did not
influence the cell cycle distribution. (D) Cell cycle distribution of Sui73 cell line (wild-type ACVR1B and SMAD4 genes). As is seen in the Sui66 cell
line, both TGFB1 and activin A increased the proportion of cells in G0/G1 phase (P = 0.014* and 0.039*, respectively) and decreased the
proportion of cells in S phase (P = 0.0034* and 0.0021*, respectively). hDEL, homozygous deletion; WT, wild-type; Columns, mean of independent
triplicate experiments; Bars, SD; *P < 0.05.
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in tumorigenicity and cellular growth.
Enhanced in vivo tumorigenicity and tumor growth of
stable ACVR1B-knockdown cell lines
We evaluated the in vivo tumorigenicity of Sui66-
transfectant cell lines and the tumor growth of Sui73-
transfectant cell lines. Sui66/shACVR1B exhibited a
significantly elevated level of tumorigenesis (Sui66/shScr-1
1/14 vs. Sui66/shACVR1B-1 8/14, P = 0.013 and Scr-2 2/
14 vs. ACVR1B-2 10/14, P= 0.0063*), and Sui73/shACVR1B
exhibited a larger tumor volume than Sui73/shScr (Sui73/
Scr-1, 167.7 ± 59.1 mm3 vs. Sui73/ACVR1B-1, 275.0 ±
56.3 mm3; P = 0.018* on day 36 and Sui73Scr-2, 105.7 ±
27.2 mm3 vs. Sui73/ACVR1B-2, 217.3 ± 81.8 mm3; P =
0.020* on day 29, respectively). (Figure 7A and B). There
was no significant difference in body weight (Sui73/Scr-1,
24.3 ± 1.0 g vs. Sui73/ACVR1B-1, 23.24 ± 1.5 g; P = 0.22
on day 36 and Sui73/Scr-2, 21.6 ± 1.3 g vs. Sui73/
ACVR1B-2, 21.1 ± 1.8 g; P = 0.61 on day 29, respectively).According to western blot analyses of the tumors and
immunostaining, the expressions of p21 were clearly el-
evated in the cancer cells in the shScr-inoculated tu-
mors, compared with the expression levels in the
shACVR1B cells (Figure 7C). In addition, the expres-
sions of Ki67 were clearly elevated in the cancer cells in
the shACVR1B-inoculated tumors (Figure 7C). These
results indicate that the ACVR1B gene is involved in
tumorigenicity and tumor growth and that it downregu-
lated the expression level of p21 in cancer cells in vivo,
similar to its effect in vitro.
Suppressed in vitro cellular growth and colony formation,
and in vivo tumorigenicity of p21-overexpressed Sui68
cell line
To determine whether p21 expression reverses the pheno-
type of the ACVR1B gene homozygous deletion, we cre-
ated a p21-overexpressed Sui68 cell line (homozygous
deletion of ACVR1B gene and wild-type SMAD4 gene)
(Figure 8A). The colony formation and cellular growth of
Figure 5 Western blot analyses using Sui66 and Sui68 cell lines. The cell lines were treated with or without 2 μM of SB431542 for 30 min,
then stimulated with TGFB1 (1 ng/mL) or activin A (10 ng/mL). β-actin was used as an internal control. (A) Phosphorylation of SMAD2 in Sui66
(wild-type ACVR1B and SMAD4 genes) and Sui68 (homozygous deletion of the ACVR1B gene and wild-type SMAD4 gene) cell lines without
SB431542. Both TGFB1 and activin A increased the phosphorylation levels of SMAD2 in Sui66 cell line. TGFB1 increased the phosphorylation level
of SMAD2, but activin A did not influence phosphorylation in Sui68 cell line. (B) Expression of p21 in Sui66 and Sui68 cell lines without SB431542.
The expression of p21 was evaluated in whole-cell lysates. Although p21 expression was increased by both TGFB1 and activin A in Sui66 cell line,
its expression was increased only by TGFB1 in Sui68 cell line. (C) Phosphorylation of SMAD2 in Sui66 and Sui68 cell lines with or without
SB431542. The cell line was stimulated by TGFB1 or activin A for 1 hour. The phosphorylation levels of SMAD2 increased in response to both
TGFB1 and activin A but were cancelled by SB431542 in Sui66 cell line. The phosphorylation level of SMAD2 increased only in response to TGFB1
and was cancelled by SB431542 in Sui68 cell line.
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with the controls (Figure 8B and C). In addition, Sui68/
EGFP exhibited a significantly elevated level of tumorigen-
esis (Sui68/EGFP 14/14 vs. Sui68/p21 8/14, P = 0.016),
and Sui68/EGFP exhibited a larger tumor volume than
Sui68/p21 on day 15 (Sui68/EGFP, 507.0 ± 83.5 mm3 vs.
Sui68/p21, 276.5 ± 95.0 mm3; P = 0.0036*) (Figure 8D).
No significant difference in body weight was seen on
day 15 (Sui68/EGFP, 20.3 ± 0.8 g vs. Sui68/p21, 20.2 ±
1.5 g; P = 0.94). These results suggest that p21 expression
reverses the phenotype arising from the homozygous dele-
tion of the ACVR1B gene.
ACVR1B and SMAD4 gene copy numbers in clinical
samples of PC
To examine the ACVR1B and SMAD4 gene copy num-
bers in PC clinical samples, we performed a TaqMan
Copy Number Assay. The ACVR1B gene copy numbers
in 6 samples (6/29, 20.7%) were less than 0.5 (Figure 9A),
while the SMAD4 gene copy numbers in 10 samples
(10/29, 34.5%) were less than 0.5 (Figure 9A). The asso-
ciation between the patient characteristics and the
ACVR1B gene status is summarized in Table 2. Interest-
ingly, 5 of the 6 samples with a deletion of the ACVR1Bgene also had a deletion of the SMAD4 gene (P = 0.011),
but no significant differences in the other patient charac-
teristics were observed between the two groups. Accord-
ing to the immunostaining results, the expressions of
p21 were clearly elevated in the cancer cells of patients
with wild-type ACVR1B and SMAD4 genes, compared
with the expression levels in patients with the homozy-
gous deletion of the ACVR1B gene (Figure 9B). Twenty-
one patients with a good performance status received
chemotherapy (gemcitabine, n = 12; gemcitabine/S1, n = 5;
S1, n = 4) at Kinki University Hospital. These regimens
were commonly used in Japan before the availability of er-
lotinib or FOLFIRINOX. Among these patients, no signifi-
cant differences in progression-free survival (PFS) or
overall survival (OS) were seen between the two groups
(Figure 9C and Table 2).
Discussion
In this study, we identified a homozygous deletion of the
ACVR1B gene in PC cell lines and clinical samples. Acti-
vin A inhibited cellular growth in the cell lines with
wild-type ACVR1B and SMAD4 genes, and ACVR1B-
knockdown enhanced cellular growth and colony forma-
tion in vitro as well as tumor growth and tumorigenicity
Figure 6 Role of ACVR1B gene in colony formation and cellular growth. To evaluate the role of the ACVR1B gene, we used stable
ACVR1B-knockdown cell lines (shACVR1B) or control (shScr). (A) Western blot analyses after activin A stimulation (10 ng/mL). In contrast to
Sui66/shScr and Sui73/shScr cell lines, ACVR1B was not expressed in Sui66/shACVR1B and Sui73/shACVR1B cell lines. SMAD2 was not phosphorylated
by activin A in Sui66/shACVR1B and Sui73/shACVR1B cell lines. β-actin was used as an internal control. (B) Influence of activin A on cellular growth.
The cell lines were stimulated with or without activin A (10 ng/mL) for 72 hours. Cell proliferation was assayed using an MTT assay. Although activin A
inhibited cellular growth in Sui66/shScr and Sui73/shScr cell lines (Sui66/shScr-1; P = 0.0014*, Sui66/shScr-2; P = 0.0032*, Sui73/shScr-1; P = 0.0085*, and
Sui73/shScr-2, P = 0.0053*, respectively), it did not influence the cellular growth in Sui66/shACVR1B and Sui73/shACVR1B cell lines (Sui66/shACVR1B-1;
P = 0.81, Sui66/shACVR1B-2; P = 0.73, Sui73/shACVR1B-1; P = 0.90, and Sui73/shACVR1B-2; P = 0.87, respectively). (C) Colony formation of Sui66-transfectant
cell lines. The colony formations in Sui66/shACVR1B cell lines were enhanced, compared with that in the control cell lines (Scr-1, 46.11 ± 8.00 vs. ACVR1B-1,
83.00 ± 16.75, P = 0.026* and Scr-2, 52.55 ± 9.24 vs. ACVR1B-2, 103.70 ± 21.00, P = 0.017*). (D) Cellular growth of Sui73-transfectant cell lines.
The cellular growth was evaluated using an MTT assay. The cellular growths in Sui73/shACVR1B cell lines were enhanced, compared with
Sui73/shScr (shScr-1 vs. shACVR1B-1, 0 h, P = 081; 24 h, P = 0.88; 48 h, P = 0.063; 72 h, P = 0.013*, and shScr-2 vs. shACVR1B-2, 0 h, P = 040;
24 h, P = 0.45; 48 h, P = 0.040*; 72 h, P = 0.014*). Columns, mean of independent triplicate experiments; Lines, mean of independent
triplicate experiments; Bars, SD; *P < 0.05.
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a tumor suppressive role in PC and that the deletion of
the ACVR1B gene mediates an aggressive cancer pheno-
type relative to PC carrying the wild-type ACVR1B gene.
Similar to our study, several articles have shown an
anti-tumorigenic effect of the activin signal. Activin A
induces growth inhibition and apoptosis mainly through
SMAD-dependent pathways in many other cancers, such
as gall bladder cancer, prostate cancer, neuroblastoma,
breast cancer, ovarian cancer, and colon cancer [22-27]. In
our study, activin A inhibited cellular growth and induced
G1 phase cell arrest in a PC cell line with wild-type
ACVR1B and SMAD4 genes via the phosphorylation of
SMAD2 and the expression of p21, while the cellular
growth of a cell line with the homozygous deletion of the
ACVR1B gene was not inhibited by activin A. In addition,
the cellular inhibitory effect of activin A and the activin-induced phosphorylation of SMAD2 were cancelled by
ACVR1B-knockdown in cell lines with wild-type ACVR1B
and SMAD4 genes. In vivo, ACVR1B-knockdown also en-
hanced the tumorigenicity and tumor growth. The Sui68
cell line (homozygous deletion of the ACVR1B gene and
the wild-type SMAD4 gene) was capable of generating
sufficient tumors, suggesting that the deletion of the
ACVR1B gene contributes to tumorigenicity even in the
presence of the wild-type SMAD4 gene. In addition,
the in vitro colony formation and cellular growth and
the in vivo tumorigenicity of the Sui68 cell line were
greatly inhibited by p21-overexpression. Thus, the anti-
tumorigenic effect of the activin signal via the SMAD
pathways and p21 was lost by ACVR1B-knockdown,
which was related to an aggressive phenotype of PC.
Interestingly, another article and the present study
both demonstrated that the inactivation of the ACVR1B
Figure 7 Xenograft study in Sui66- and Sui73-transfectant cell lines. (A) Tumorigenesis in vivo. To evaluate tumorigenicity in vivo, a
suspension of 5 × 106 Sui66-transfectant cells (in 50 μL PBS) were subcutaneously inoculated into both flanks of nude mice (n = 7). Tumor
formation was assessed every 2 or 3 days. Sui66/sh-ACVR1B exhibited a significantly elevated level of tumorigenesis in vivo (Scr-1 1/14 vs.
ACVR1B-1 8/14, P = 0.013* and Scr-2 2/14 vs. ACVR1B-2 10/14, P = 0.0063*). (B) Tumor growth in vivo. To assess the tumor growth in vivo, a
suspension of 5 × 106 Sui73-transfectant cell lines (in 50 μL PBS) with 50 μL of Matrigel were subcutaneously inoculated into the right flank of
nude mice (n = 5). The tumor volume was assessed every 2 or 3 days. Sui73/shACVR1B exhibited a significantly elevated tumor volume (Sui73/Scr-1,
167.7 ± 59.1 mm3 vs. Sui73/ACVR1B-1, 275.0 ± 56.3 mm3; P = 0.018* on day 36 and Sui73Scr-2, 105.7 ± 27.2 mm3 vs. Sui73/ACVR1B-2, 217.3 ± 81.8 mm3;
P = 0.020* on day 29, respectively). Lines, mean of 5 tumors; Error bars, SD; *P < 0.05. (C) Western blot analyses of the tumors and immunostaining. The
expressions of p21 were clearly elevated in cancer cells in shScr-inoculated tumors, compared with the expression levels in shACVR1B cells. The
expressions of Ki67 were also clearly elevated in the cancer cells in the shACVR1B-inculated tumors. β-actin was used as an internal control.
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SMAD4 gene [19]. The TGFB and activin signals have
non-SMAD pathways, and the ERK/MAPK signal and
the PI3K/AKT signal are representative signals that are
associated with cellular growth and survival [30]. In the
Sui70 cell line (wild-type ACVR1B gene and the homo-
zygous deletion of the SMAD4 gene), however, activin A
did not influence the cellular growth, and neither the
phosphorylation of ERK1/2 nor that of AKT was en-
hanced. Approximately 95% of PC, including the Sui70
cell line has a K-ras mutation [5-8], and both ERK1/2
and AKT are phosphorylated in the Sui70 cell line be-
cause of this mutation [31]. Therefore, non-SMAD path-
ways may have little effect on the aggressiveness of PC
carrying the wild-type ACVR1B gene and a homozygous
deletion of the SMAD4 gene. In addition, some other re-
ports have suggested that the inactivation of a TGFB re-
ceptor is not mutually exclusive with that of the SMAD4
gene, since both members are known to be genetically
inactivated in some tumors [32,33]. Therefore, thesefindings would fit with a combined input model, which
could explain the observed coexistence of the genetic
inactivations of these genes.
Pancreatic-specific TGFBR2 or SMAD4-knockout mice
with active K-ras expression reportedly developed PC
[16,17]. However, systemic ACVR1B-knockout mice do
not survive beyond embryonic day 9.5 [34], and pancreatic-
specific ACVR1B-knockout mice have not been previously
studied. Considering the tumor suppressive role of the
ACVR1B gene, the development of PC in pancreatic-
specific ACVR1B-knockout mice seems reasonable. In
contrast to our results, however, a recent study has
demonstrated that Nodal/Activin signal is associated
with self-renewal and the tumorigenicity of PC stem
cells [20]. Therefore, to investigate these findings, fur-
ther research is required.
Since the clinical DNA samples were obtained using
needle biopsies, the inclusion of some normal pancreas
tissue was unavoidable. Thus, the copy number data does
not exactly reflect that for cancer tissue. In addition, the
Figure 8 Role of p21 gene in colony formation and cellular growth in vitro and tumorigenicity in vivo. To see if p21 expression reverses
the phenotype for ACVR1B gene homozygous deletion, we created a p21-overexpressed Sui68 cell line (homozygous deletion of ACVR1B gene
and wild-type SMAD4 gene). (A) Western blot analyses. The overexpression of p21 was confirmed using western blot analyses in the Sui68/p21
cell line. β-actin was used as an internal control. (B) Colony formation of Sui68-transfectant cell lines. The colony formation in the Sui68/p21 cell
line was suppressed, compared with that in the control cell line (EGFP, 28.0 ± 9.17 vs. p21, 0.89 ± 0.19, P = 0.035*). Columns, mean of independent
triplicate experiments; Bars, SD; *P < 0.05. (C) Cellular growth of Sui68-transfectant cell lines. The cellular growth was evaluated using an MTT assay.
Cellular growth in the Sui68/p21 cell line was suppressed, compared with Sui68/EGFP (0 h, P = 065; 24 h, P = 0.074; 48 h, P = 0.053; 72 h, P = 0.030*).
Lines, mean of independent triplicate experiments; Bars, SD; *P < 0.05. (D) Tumorigenesis in vivo. To evaluate tumorigenicity in vivo, a suspension of
5 × 106 Sui68-transfectant cells (in 50 μL PBS) were subcutaneously inoculated into both flanks of nude mice (n = 7). Sui68/EGFP exhibited a significantly
elevated level of tumorigenesis (Sui68/EGFP 14/14 vs. Sui68/p21 8/14, P = 0.016). (E) Tumor growth in vivo. To evaluate the tumor growth, a suspension
of 5× 106 Sui68-transfectant cells (in 50 μL PBS) with 50 μL of Matrigel were subcutaneously inoculated into the right flanks of nude mice (n = 5).
Sui68/EGFP exhibited a larger tumor volume than Sui68/p21 on day 15 (Sui68/EGFP, 507.0 ± 83.5 mm3 vs. Sui68/p21, 276.5 ± 95.0 mm3; P = 0.0036*).
Lines, mean of five tumors; Bars, SD; *P < 0.05.
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cohort has many limitations. No significant differences in
the PFS or OS were observed between the patients with
ACVR1B gene deletions and those without. To confirm
the clinical importance of the ACVR1B gene deletion, lar-
ger studies including more precise genome evaluations are
needed.
Conclusion
We identified the homozygous deletion of the ACVR1B
gene in PC cell lines and clinical samples. Our experimen-
tal findings indicate that the activin signal has a tumor
suppressive role and that the deletion of the ACVR1B gene
may mediate an aggressive cancer phenotype in PC.
Materials and methods
Cell culture, ligands, and reagents
Human PC cell lines (Sui65, Sui66, Sui67, Sui68, Sui70,
Sui71, Sui73, and Sui74) were maintained in RPMI-1640medium (Sigma-Aldrich, St. Louis, MO) with 10% FBS
(GIBCO BRL, Grand Island, NY) (Table 1) [31]. The cell
lines were maintained in a 5% CO2-humidified atmos-
phere at 37˚C.
TGFB1 and activin A were both purchased from R&D
Systems (Minneapolis, MN). The ACVR1B/TGFBR1/
ACVR1C-specific inhibitor SB431542 was purchased
from Sigma-Aldrich.
Array-based comparative genomic hybridization
The Genome-wide Human SNP Array 6.0 (Affymetrix,
Santa Clara, CA) was used to perform array-CGH on
genomic DNA from each of the PC cell lines as described
previously [35]. The GeneChip Human Mapping 250 K
Nsp Array (Affymetrix) was used to perform array-CGH
on genomic DNA from each of the cell lines. A total of
250 ng of genomic DNA was digested with Nsp I (250 K)
or both Nsp I and Sty I in independent parallel reactions
(SNP6.0), subjected to restriction enzymes, ligated to the
Figure 9 Copy numbers of ACVR1B and SMAD4 genes, immunostaining of p21, and Kaplan-Meier curves for PFS and OS in PC clinical
samples. (A) The copy numbers were analyzed using TaqMan copy number assays. Copy number of the ACVR1B gene. Six samples (6/29, 20.7%)
had a copy number of less than 0.5 (deletion). Copy number of the SMAD4 gene. Ten samples (10/29, 34.5%) had a copy number of less than 0.5
(deletion). (B) Immunostaining of p21. The expressions of p21 were clearly elevated in the cancer cells of patients with wild-type ACVR1B and
SMAD4 genes, compared with the expression levels in those of patients with a homozygous deletion of the ACVR1B gene. WT, wild-type; hDEL,
homozygous deletion. (C) Kaplan-Meier curves for PFS and OS. Among 21 patients who received chemotherapy, no significant differences in PFS
or OS were seen between the patients without a homozygous deletion of the ACVR1B gene and those with such a deletion (median PFS, 252 days
vs. 167 days, P = 0.89, and median OS, 344 days vs. 215 days, P = 0.66, respectively).
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and TITANIUM Taq DNA Polymerase (Clontech, Palo
Alto, CA). The PCR products were then quantified, frag-
mented, end-labeled, and hybridized onto a GeneChip
Human Mapping 250 K Nsp Array or a Genome-wide
Human SNP6.0 Array. After washing and staining in Flu-
idics Station 450 (Affymetrix), the arrays were scanned to
generate CEL files using the GeneChip Scanner 3000 and
GeneChip Operating Software, ver.1.4.
Copy number assay for ACVR1B and SMAD4 genes
The copy numbers for ACVR1B and SMAD4 genes were
determined using commercially available and pre-designed
TaqMan Copy Number Assays (Applied Biosystems, Foster
City, CA) as described previously [36]. The primer IDs used
for the ACVR1B and SMAD4 genes were Hs06931689_cn
(intron 1) and Hs07120826_cn (intron 1), respectively. The
TERT locus was used for the internal reference copy num-
ber. Human Genomic DNA (TaKaRa) was used as a normal
control. Real-time genomic PCR was performed in a total
volume of 20 μL in each well, which contained 10 μL of
TaqMan genotyping master mix and 20 ng of genomicDNA and each primer. The PCR conditions were 95°C
for 10 min and 40 cycles of 95°C for 15 sec and 60°C
for 1 min; the resulting products were detected using
the ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystems). Data were analyzed using SDS
2.2 software and CopyCaller software (Applied Biosys-
tems). Samples with a gene copy number of less than
0.5 were defined as having a copy number of 0 (dele-
tion of the gene), while those with a gene copy number
of 0.5 or more but less than 1.5 were defined as having
a copy number of 1 and those with a gene copy number
of 1.5 or more but less than 2.5 were defined as having
a copy number of 2.
Real-time RT-PCR
One microgram of total RNA from each of the PC
cell lines and normal pancreas tissue purchased from
Clontech were converted to cDNA using the GeneAmp
RNA-PCR kit (Applied Biosystems). Real-time PCR was
performed using the Applied Biosystems 7900 HT Fast
Real-time PCR System (Applied Biosystems), as de-
scribed previously [28] under the following conditions:
Table 2 Patient characteristics and the association with
ACVR1B gene status






<70 years 15 3 0.65
≥ 70 years 8 3
Gender
Male 12 3 1.00
Female 11 3
Primary size
<2 cm 18 5 1.00
≥2 cm 5 1
Lymph node metastasis
Negative 4 0 0.55
Positive 19 6
Distant metastasis
Negative 10 4 0.39
Positive 13 2
SMAD4 gene status
Not deletion 18 1 0.011*
Deletion 5 5
Treatment




PR 7 1 1.00
SD or PD 10 3
Median PFS (days) 252 167 0.89
Median OS (days) 344 215 0.66
ACVR1B, activin receptor A, type IB; PR, partial response; SD, stable disease; PD,
progressive disease; PFS, progression-free survival; OS, overall survival. PFS and
OS were analyzed by log-rank test and the others by Fisher exact test.
Legend: Six patients (6/29, 20.7%) had a deletion of ACVR1B gene, 10 patients
(10/29, 34.5%) had a deletion of SMAD4 gene. Five of the 6 patients with a
deletion of the ACVR1B gene also had a deletion of the SMAD4 gene (P = 0.011),
but no significant differences in the other patient characteristics were observed
between the two groups. Among 21 patients who received chemotherapy, no
significant differences in PFS or OS were seen between the two groups.
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for 1 min. Glyceraldehyde 3 phosphate dehydrogenase
(GAPD, NM_002046) was used to normalize the expres-
sion levels in subsequent quantitative analyses. To amp-
lify the target genes, the following primers were used:
ACVR1B-F, CAGCAGAACCTTGGCGGTTTA; ACVR1B-
R, GTTGGCAGATCCCAGAGGCTAC; SMAD4-F, CAG
CTATGCCAGAAGCCAGA; SMAD4-R, GAACTCCTGG
GACTTTCAACTGAC; GAPD-F, GCACCGTCAAGGCTGAGAAC; GAPD-R, ATGGTGGTGAAGACGCCAGT.
The experiment was performed in triplicate.Plasmid construction, viral production, and stable
transfectants
A short hairpin RNA (shRNA)-targeting ACVR1B gene
was constructed using oligonucleotides encoding small
interfering RNA directed against the ACVR1B gene and
a non-specific target as follows: GAATTGCTCATCGA-
GACTT and GGCTTGTTTCTGACTATCA for ACVR1B
shRNA (shRNA ACVR1B-1 and shRNA ACVR1B-2, re-
spectively), and ACTTGGTTCGCGTATCAAA and CCA
TATTGCGCGTTGATTT for control shRNA (shRNA
scramble-1 and shRNA scramble-2, respectively). The
method was described previously [28]. Briefly, the oligo-
nucleotides were cloned into an RNAi-Ready pSIREN-
RetroQZsGreen vector (Clontech). A pVSV-G vector
(Clontech) for the constitution of the viral envelope and
the RNAi-Ready pSIREN-RetroQZsGreen constructs were
cotransfected into gpIRES-293 cells using FuGENE6 trans-
fection reagent (Roche Diagnostics, Basel, Switzerland).
After 48 hours of transfection, the culture medium was
collected and the viral particles were concentrated by cen-
trifugation at 15,000 × g for 3 hours at 4°C. The viral pellet
was then resuspended in fresh RPMI-1640 medium. The
titer of the viral vector was calculated by counting the
green-positive cells that were infected by serial dilutions
of virus-containing media, and the multiplicity of infection
was then determined. The viral vectors were designated as
pSIREN-shACVR1B-1, pSIREN-shACVR1B-2, pSIREN-
shScr-1, and pSIREN-shScr-2. The stable transfectants ex-
pressing shRNA ACVR1B-1, shRNA ACVR1B-2, shRNA
scramble-1 or shRNA scramble-2 in the Sui66 and Sui73
cell lines were designated as Sui66/shACVR1B (Sui66/
shACVR1B-1 and Sui66/shACVR1B-2), Sui66/shScr (Sui66/
shScr-1 and Sui66/shScr-2), Sui73/shACVR1B (Sui73/
shACVR1B-1 and Sui73/shACVR1B-2), and Sui73/shScr
(Sui73/shScr-1 and Sui73/shScr-2), respectively.
A full-length cDNA fragment encoding the human p21
gene was introduced into a pQCLIN retroviral vector
(Clontech) together with enhanced green fluorescent pro-
tein (EGFP) following the internal ribosome entry site se-
quence (IRES) to monitor the expression of the inserts
indirectly. The methods used for viral production and the
stable transfectant were described above. The vectors and
stable viral transfectant Sui68 cell line was designated as
pQCLIN-EGFP, pQLCIN-p21, Sui68/EGFP and Sui68/
p21, respectively.Antibody
A goat antibody specific for ACVR1B was obtained from
R&D Systems. Rabbit antibodies specific for SMAD2,
phospho-SMAD2, SMAD4, AKT, phospho-AKT, ERK1/
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from Cell Signaling (Beverly, MA).
Western blot analysis
A western blot analysis was performed as described pre-
viously [28]. Briefly, subconfluent cells were washed with
cold phosphate-buffered saline (PBS) and harvested with
Lysis A buffer containing 1% Triton X-100, 20 mM
Tris–HCl (pH7.0), 5 mM EDTA, 50 mM sodium chloride,
10 mM sodium pyrophosphate, 50 mM sodium fluoride,
1 mM sodium orthovanadate, and a protease inhibitor
mix, Complete™ (Roche Diagnostics). Whole-cell lysates
were separated using a 5%-20% SDS-PAGE and were blot-
ted onto a polyvinylidene fluoride membrane. After block-
ing with 3% bovine serum albumin in a TBS buffer
(pH8.0) with 0.1% Tween-20, the membrane was probed
with primary antibody. After rinsing twice with TBS buf-
fer, the membrane was incubated with horseradish
peroxidase-conjugated secondary antibody and washed,
followed by visualization using an ECL detection system
(GE Healthcare, Buckinghamshire, United Kingdom) and
LAS-3000 (Fujifilm, Tokyo, Japan). When the influence of
the ligands was evaluated, the cultured medium was re-
placed with 1% FBS medium 6 hours before exposure to
the ligands.
Cellular growth assay
The Sui66-, Sui68-, and Sui73-transfectant cell lines were
incubated on 96-well plates at a density of 2,000/well with
200 μL of cultured medium at 37°C in 5% CO2. After
24, 48, or 72 hours of incubation, 20 μL of MTT [3-(4,
5-dimethyl-thiazoyl-2-yl)2,5-diphenyltetrazolium bromide]
solution (Sigma-Aldrich) was added and the culture
medium was discarded; the wells were then filled with
DMSO. The absorbance of the cultures at 570 nm was
measured using VERSAmax (Japan Molecular Devices,
Tokyo, Japan). To evaluate growth in the presence of li-
gands, we also used an MTT assay. The cell lines (2,000/
well) were transferred to 96-well plates and cultured
using 1% FBS medium for 24 hours at 37°C. Then, the
ligands (TGFB1: 0, 0.1, 1, and 10 ng/mL; activin A: 0, 1,
10, and 100 ng/mL) were added and the incubation was
further continued for 72 hours at 37°C using 1% FBS
medium. The average O.D. values of the 6 wells were
used for a single experiment, and the experiment was
performed in triplicate.
Colony formation assay
Sui66- and Sui73-transfectant cell lines were seeded into
6-well plates at a density of 200 cells/well, and Sui68-
transfectant cell lines were seeded into 6-well plates at a
density of 500 cells/well. After 2 weeks, the cells were
washed with PBS and fixed with 4% paraformaldehyde
for 10 min and then stained with 0.1% crystal violet for15 min; the colonies were then counted under a light
microscope. The experiment was performed in triplicate.
Cell cycle distribution analysis
The cell cycle analyses were performed as described previ-
ously [37]. Briefly, cell lines were seeded into 6-cm dishes
of 2 × 105 cells and cultured using 1% FBS medium for
24 hours at 37°C. Then, the ligands (TGFB1, 1 ng/mL;
activin A, 10 ng/mL) were added, and the incubation was
further continued for 48 hours at 37°C using 1% FBS
medium. Cells were harvested by trypsinization, washed
twice with PBS, and fixed with cold 70% ethanol at 4°C for
30 min. Then, the cells were washed twice with PBS and
stained using propidium iodide/RNase Staining Buffer
(BD Biosciences, San Jose, CA) at room temperature for
15 min. The cells were analyzed using a flow cytometer
(BD FACSCalibur™, BD Biosciences), and the cell cycle
analysis was performed using ModFit LT software. The ex-
periment was performed in triplicate.
Xenograft studies
Nude mice (BALB/c nu/nu; 6-week-old females; CLEA
Japan, Tokyo, Japan) were used for the in vivo studies
and were cared for in accordance with the recommenda-
tions for the Handling of Laboratory Animals for Bio-
medical Research compiled by the Committee on Safety
and Ethical Handling Regulations for Laboratory Ani-
mals Experiments, Kinki University. The ethical proce-
dures followed and met the requirements of the United
Kingdom Coordinating Committee on Cancer Research
guidelines. To evaluate tumorigenicity, a suspension of
5 × 106 Sui66- and Sui68-transfectant cells (in 50 μL
PBS) were subcutaneously inoculated into both flanks of
nude mice (n = 7). To evaluate the tumor growth, a sus-
pension of 5 × 106 Sui68- and Sui73-transfectant cells (in
50 μL PBS) with 50 μL of Matrigel were subcutaneously
inoculated into the right flanks of nude mice (n = 5). The
tumor volume was calculated as the length × width2 × 0.5.
The tumor formation and volume were assessed every 2
to 3 days. At the end of the experiment, the mice were
sacrificed and the xenografts were resected, fixed in 10%
buffered formalin for 6 to 10 hours, and processed for
histologic analysis. The method was described previ-
ously [38].
Patients and samples
A total of 29 patients who had been diagnosed as having
unresectable PC based on the results of an endoscopic
biopsy performed at Kinki University Hospital between
April 2007 and March 2008 were enrolled. This study
was retrospectively performed and was approved by the
institutional review board of the Kinki University Faculty
of Medicine. The staging of the PC was determined ac-
cording to the TNM classification. Among those who
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apy, the PFS was defined as the time from the initiation
of chemotherapy until the first observation of disease
progression or death from any cause, OS was defined as
the time from the initiation of chemotherapy until death
from any cause. The response to chemotherapy was evalu-
ated at one month after the start of therapy and every
2 months thereafter using computed tomography accord-
ing to the Response Evaluation Criteria in Solid Tumors.
DNA extraction
The endoscopic biopsy samples were immediately stored
at −80°C. Other biopsy samples obtained from the same
location were reviewed by a pathologist to confirm the
presence of tumor cells. The DNA was extracted using a
QIAamp DNA Micro kit (Qiagen, Hilden, Germany) as
described previously [36]. The DNA concentration was
determined using the NanoDrop2000 (Thermo Fisher
Scientific, Waltham, MA).
Statistical analysis
Continuous variables were analyzed using the Student
t-test, and the results were expressed as the average and
standard deviations (SD). Dichotomous variables were an-
alyzed using the Fisher exact test. PFS and OS were ana-
lyzed using the Kaplan-Meier method and were compared
among groups using the log-rank test. The statistical ana-
lyses were two-tailed and were performed using Microsoft
Excel (Microsoft, Redmond, WA). A P-value of less than
0.05 was considered statistically significant.
Additional file
Additional file 1: Effects of ligands on the Sui70 cell line (wild-type
ACVR1B gene and homozygous deletion of SMAD4 gene). A. Influence
of TGFB1 and activin A on cellular growth in the Sui70 cell line. Both TGFB1
(0.1 ng/mL, P = 0.42; 1 ng/mL, P = 0.65; 10 ng/mL, P = 0.30) and activin A
(1 ng/mL, P = 0.38; 10 ng/mL, P = 0.47; 100 ng/mL, P = 0.35) did not
influence the cellular growth. hDEL, homozygous deletion; WT, wild-type.
B. Western blot analyses for non-SMAD pathway and p21. Both AKT and
ERK1/2 had already been phosphorylated, and the phosphorylation was
not enhanced by activin A. The expression of p21 was not changed
by activin A.
Abbreviations
ACVR: Activin A receptor; CGH: Comparative genomic hybridization;
OS: Overall survival; PBS: Phosphate-buffered saline; PC: Pancreatic cancer;
PFS: Progression-free survival; RT-PCR: Reverse-transcription PCR;
Scr: Scramble; SD: Standard deviations; sh: Short hairpin; TGFB: Transforming
growth factor beta; TGFBR: Transforming growth factor beta receptor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YT designed and participated in the experiments and drafted the
manuscript. HS and MK collected clinical samples. HH and MT carried out the
experiments with cells. VM and YF carried out the in vivo experiments. YK
and KS carried out the clinical sample analyses. AI reviewed the histology. ST
performed the statistical analysis. MK and KN conceived the study,participated in its design and coordination, and helped to draft the
manuscript. All the authors have read and approved the final manuscript.Acknowledgment
We thank Mr. Shinji Kurashimo, Mr. Yoshihiro Mine, Ms. Eiko Honda, Ms.
Tomoko Kitayama, and Ms. Ayaka Kurumatani for their technical assistance.
This work was supported in part by the Third-Term Comprehensive 10-Year
Strategy for Cancer Control and Grant-in Aid for Japan Society for Promotion
of Science Fellows.
Author details
1Department of Genome Biology, Kinki University Faculty of Medicine, 377-2
Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. 2Department of
Gastroenterology and Hepatology, Kinki University Faculty of Medicine,
Osaka-Sayama, Osaka, Japan. 3Department of Pathology, Kinki University
Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Received: 13 November 2013 Accepted: 20 May 2014
Published: 27 May 2014References
1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ,
Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G,
Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute
of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared
with gemcitabine alone in patients with advanced pancreatic cancer:
a phase III trial of the National Cancer Institute of Canada Clinical
Trials Group. J Clin Oncol 2007, 25:1960–1966.
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y,
Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J,
Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B,
Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of
Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med 2011, 364:1817–1825.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T,
Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D,
Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E,
Wei X, Iglesias J, Renschler MF: Increased survival in pancreatic cancer with
nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691–1703.
4. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
5. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nat Rev
Cancer 2002, 2:897–909.
6. Singh P, Srinivasan R, Wig JD: Major molecular markers in pancreatic
ductal adenocarcinoma and their roles in screening, diagnosis,
prognosis, and treatment. Pancreas 2011, 40:644–652.
7. Macgregor-Das AM, Iacobuzio-Donahue CA:Molecular pathways in pancreatic
carcinogenesis. J Surg Oncol 2013, 107:8–14.
8. Baker CH, Solorzano CC, Fidler IJ: Blockade of vascular endothelial growth
factor receptor and epidermal growth factor receptor signaling for
therapy of metastatic human pancreatic cancer. Cancer Res 2002,
62:1996–2003.
9. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN,
Kern SE, Hruban RH: Immunohistochemical evaluation of HER-2/neu
expression in pancreatic adenocarcinoma and pancreatic intraepithelial
neoplasms. Hum Pathol 1996, 27:119–124.
10. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C,
Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T,
Goldstein L, King T, Tsai JY, Kennedy T: Herceptin and gemcitabine for
metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest
2004, 22:706–712.
11. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P,
Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A,
Schmoor C, Geissler M: Multicentre phase II trial of trastuzumab and
capecitabine in patients with HER2 overexpressing metastatic pancreatic
cancer. Br J Cancer 2012, 106:1033–1038.
12. Ikushima H, Miyazono K: TGFbeta signalling: a complex web in cancer
progression. Nat Rev Cancer 2010, 10:415–424.
13. Akhurst RJ, Hata A: Targeting the TGFβ signalling pathway in disease. Nat
Rev Drug Discov 2012, 11:790–811.
Togashi et al. Molecular Cancer 2014, 13:126 Page 15 of 15
http://www.molecular-cancer.com/content/13/1/12614. Hilbig A, Oettle H: Transforming growth factor beta in pancreatic cancer.
Curr Pharm Biotechnol 2011, 12:2158–2164.
15. Birnbaum DJ, Mamessier E, Birnbaum D: The emerging role of the TGFβ
tumor suppressor pathway in pancreatic cancer. Cell Cycle 2012,
11:683–686.
16. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CV,
Moses HL: Aggressive pancreatic ductal adenocarcinoma in mice caused
by pancreas-specific blockade of transforming growth factor-beta
signaling in cooperation with active Kras expression. Genes Dev 2006,
20:3147–3160.
17. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX,
Hruban RH, Adsay NV, Tuveson DA, Hingorani SR: Kras(G12D) and Smad4/
Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms
and invasive adenocarcinoma of the pancreas. Cancer Cell 2007, 11:229–243.
18. Kleeff J, Ishiwata T, Friess H, Büchler MW, Korc M: Concomitant over-
expression of activin/inhibin beta subunits and their receptors in human
pancreatic cancer. Int J Cancer 1998, 77:860–868.
19. Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, Kern SE:
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic
carcinoma. Proc Natl Acad Sci U S A 2001, 98:3254–3257.
20. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I,
Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E,
Hidalgo M, Cebrián DÁ, Heuchel R, Lour M, Berger F, Bartenstein P, Aicher A,
Heeschen C: Nodal/Activin signaling drives self-renewal and tumorigenicity
of pancreatic cancer stem cells and provides a target for combined drug
therapy. Cell Stem Cell 2011, 9:433–446.
21. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM,
Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, Yeo CJ,
Hruban RH, Kern SE: Evidence of selection for clones having genetic
inactivation of the activin A type II receptor (ACVR2) gene in
gastrointestinal cancers. Cancer Res 2003, 63:994–999.
22. Bauer J, Sporn JC, Cabral J, Gomez J, Jung B: Effects of activin and TGFβ
on p21 in colon cancer. PLoS One 2012, 7:e39381.
23. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, Risbridger GP:
Expression of activin A and follistatin core proteins by human prostate
tumor cell lines. Endocrinology 1999, 140:5303–5309.
24. Yokomuro S, Tsuji H, Lunz JG 3rd, Sakamoto T, Ezure T, Murase N, Demetris AJ:
Growth control of human biliary epithelial cells by interleukin 6,
hepatocyte growth factor, transforming growth factor beta1, and activin A:
comparison of a cholangiocarcinoma cell line with primary cultures of
non-neoplastic biliary epithelial cells. Hepatology 2000, 32:26–35.
25. Panopoulou E, Murphy C, Rasmussen H, Bagli E, Rofstad EK, Fotsis T: Activin
A suppresses neuroblastoma xenograft tumor growth via antimitotic
and antiangiogenic mechanisms. Cancer Res 2005, 65:1877–1886.
26. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK: Activin A mediates
growth inhibition and cell cycle arrest through Smads in human breast
cancer cells. Cancer Res 2005, 65:7968–7975.
27. Ramachandran A, Marshall ES, Love DR, Baguley BC, Shelling AN: Activin is
a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett
2009, 285:157–165.
28. Kaneda H, Arao T, Matsumoto K, De Velasco MA, Tamura D, Aomatsu K,
Kudo K, Sakai K, Nagai T, Fujita Y, Tanaka K, Yanagihara K, Yamada Y,
Okamoto I, Nakagawa K, Nishio K: Activin A inhibits vascular endothelial
cell growth and suppresses tumour angiogenesis in gastric cancer. Br J
Cancer 2011, 105:1210–1217.
29. Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other
cancers. Cancer Cell 2003, 4:425–429.
30. Mu Y, Gudey SK, Landström M: Non-Smad signaling pathways. Cell Tissue
Res 2012, 347:11–20.
31. Yanagihara K, Takigahira M, Tanaka H, Arao T, Aoyagi Y, Oda T, Ochiai A,
Nishio K: Establishment and molecular profiling of a novel human
pancreatic cancer panel for 5-FU. Cancer Sci 2008, 99:1859–1864.
32. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE: Genetic
alterations of the transforming growth factor beta receptor genes in
pancreatic and biliary adenocarcinomas. Cancer Res 1998, 58:5329–5332.
33. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh
JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B,
Willson JK, Markowitz S: Mutational inactivation of transforming growth
factor beta receptor type II in microsatellite stable colon cancers. Cancer
Res 1999, 59:320–324.34. Gu Z, Nomura M, Simpson BB, Lei H, Feijen A, van den Eijnden-van RJ,
Donahoe PK, Li E: The type I activin receptor ActRIB is required for egg
cylinder organization and gastrulation in the mouse. Genes Dev 1998,
12:844–857.
35. Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D, Aomatsu K, Kudo K,
Kaneda H, Fujita Y, Matsumoto K, Yamada Y, Yanagihara K, Sekijima M,
Nishio K: Integrated analysis of whole genome exon array and
array-comparative genomic hybridization in gastric and colorectal cancer
cells. Cancer Sci 2012, 103:221–227.
36. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H,
Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y: FGFR2 gene
amplification and clinicopathological features in gastric cancer. Br J
Cancer 2012, 106:727–732.
37. Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, Aomatsu K,
Fujita Y, Watanabe T, Saijo N, Kotani Y, Nishimura Y, Nishio K: Bortezomib
potentially inhibits cellular growth of vascular endothelial cells through
suppression of G2/M transition. Cancer Sci 2010, 101:1403–1408.
38. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K,
De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I,
Nakagawa K, Nishio K: FOXQ1 is overexpressed in colorectal cancer and
enhances tumorigenicity and tumor growth. Cancer Res 2010,
70:2053–2063.
doi:10.1186/1476-4598-13-126
Cite this article as: Togashi et al.: Homozygous deletion of the activin A
receptor, type IB gene is associated with an aggressive cancer phenotype in
pancreatic cancer. Molecular Cancer 2014 13:126.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
